Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324582 · ClinicalTrials.gov registry record · Phase 1
MK-3475/BCG in High Risk Superficial Bladder Cancer
A Phase 1 study, sponsored by Southern Illinois University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02324582: Completed Phase 1 study, sponsored by Southern Illinois University.
NCT02324582 is a Phase 1 study that has completed, run by Southern Illinois University. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02324582, a Phase 1 study, has completed, sponsored by Southern Illinois University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a single center Phase I safety and efficacy study of MK-3475 therapy used in combination with bladder infused BCG treatment for patients, 18 years or older, with high risk superficial bladder cancer (cancer not yet involving the muscle of the bladder wall) who have had removal of their bladder tumor. Patients will be enrolled to a single treatment group of a fixed dose of MK 3475 and BCG.
Primary Outcome
Grade and quantity of treatment related adverse events. Due to the small sampling of subjects, no statistical analysis will be performed. Descriptive statistics in the form of counts calculated as percentages will be reported.
Interventions
- DRUG Intravenous MK-3475/ Intravesical BCG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-06 |
| Est. Completion | 2023-03-27 |
| Phase | Phase 1 |
What the finished NCT02324582 record still lists
NCT02324582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which Intravenous MK-3475/ Intravesical BCG is the first listed.
NCT02324582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02324582 about?
NCT02324582 is a clinical study titled "MK-3475/BCG in High Risk Superficial Bladder Cancer". This is a single center Phase I safety and efficacy study of MK-3475 therapy used in combination with bladder infused BCG treatment for patients, 18 years or older, with high risk superficial bladder cancer (cancer not yet involving the muscle of the bladder wall) who have had removal of their bladd...
What is the current status of trial NCT02324582?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2015-06. Estimated completion is 2023-03-27.
What interventions are being tested in trial NCT02324582?
The interventions under investigation include: Intravenous MK-3475/ Intravesical BCG (DRUG).
Who is sponsoring clinical trial NCT02324582?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02324582's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia